Porphysome Engineered With Specific Protein Binding Sites as a Multimodal Theranostic Nanocarrier for Targeted Protein Delivery

Chem Biodivers. 2024 Jun;21(6):e202400348. doi: 10.1002/cbdv.202400348. Epub 2024 May 3.

Abstract

The immobilization of proteins on the surface of carriers is challenging due to the loss of protein structure and function in this process. Here, we report the development of the protein immobilization on the surface of the metallated-porphyrin complex in the porphysome nanocarrier. The conjugated Ni-porphyrin to fatty acid (as a tail) has been synthesized and independently placed at the depth of the bilayer center of Dipalmitoylphosphatidylcholine (DPPC) in which the Ni-porphyrin was at the polar region of the membrane and is thus superficial. This porphysome (DPPC: Ni-porphyrin, 4 : 1 mole ratio) was formed by supramolecular self-assembly with a diameter of 173±7 nm and zeta potential -8.5±3.4 mv, which exhibited no significant toxicity at the experimental concentrations and acceptable cellular uptake on MCF-7 cells. The physicochemical properties and specific protein binding sites of the firefly luciferase as a model protein into the porphysome (1 : 2 mole ratio) show the conjugation efficiency about 80 % and the conformation of protein was completely maintained. Furthermore, bioluminescence assay and SDS-PAGE confirmed the preservation of protein function. The stabilized platform of porphyrin-lipid structure can potentially improve the efficacy of protein functionality for a particular display, shifting porphysomes from a simple carrier to a therapeutic agent.

Keywords: Fluorescence imaging; Ni-Porphyrin complex; Porphysome; Protein activity; Specific binding site; Targeted drug delivery.

MeSH terms

  • 1,2-Dipalmitoylphosphatidylcholine / chemistry
  • Binding Sites / drug effects
  • Cell Survival / drug effects
  • Drug Carriers / chemistry
  • Drug Delivery Systems
  • Humans
  • MCF-7 Cells
  • Nanoparticles / chemistry
  • Particle Size
  • Porphyrins* / chemistry
  • Porphyrins* / pharmacology
  • Theranostic Nanomedicine

Substances

  • Porphyrins
  • Drug Carriers
  • 1,2-Dipalmitoylphosphatidylcholine

Grants and funding